As a result, these TAK1 mutants defected TAK1's oncogenic functions to promote cancer cell proliferation, tumor growth in vivo, and elevate p65 downstream targeted genes such as TNFα, IL‐6 and IL‐1β. (Figure 3P–S; Figure S6J–O, Supporting Information). The gene discussed is IL6; the disease is neoplasm.